Themis Medicare Limited

530199

INE083B01024

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 06:30:18 12/06/2026 BST			5-day change	1st Jan Change
102.30 ^INR	+2.10%		-1.92%	+1.64%

05-28	Themis Medicare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
05-28	Themis Medicare Limited Recommends Final Dividend for the Financial Year Ended 31 March, 2026	CI

Themis Medicare Limited announced that it expects to receive INR 114.619127 million in funding

Published on 02/24/2026

S&P Capital IQ

THEMIS MEDICARE LIMITED

+2.10%

Themis Medicare Limited Announces a private placement to issue 4,595,795 Convertible Equity Warrants at a price of INR 99.76 per share for gross proceeds of INR 24.94 per share for gross proceeds of INR 114,619,127.3 on February 25, 2026. Exercise price is INR 74.82.

Latest news about Themis Medicare Limited

05-28	Themis Medicare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
05-28	Themis Medicare Limited Recommends Final Dividend for the Financial Year Ended 31 March, 2026	CI
03-27	Vividhmargi Investment Pvt. Ltd. acquired an additional 10.75% stake in Themis Medicare Limited from Vividh Distributors Private Limited and Themis Distributors Pvt Ltd.	CI
02-24	Themis Medicare Limited announced that it expects to receive INR 114.619127 million in funding	CI
02-14	Themis Medicare Limited Announces Executive Changes	CI
02-13	Themis Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
11-13	Themis Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI
11-10	Themis Medicare Limited Announces Cessation of Manjul Sandhu as Independent Woman Director, Effective November 10, 2025	CI
01/08/25	Themis Medicare Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	CI
01/08/25	Themis Medicare Limited Approves Appointment of Viraj Save as Executive President - Sales & Marketing, Effective 1st August, 2025	CI
13/06/25	Themis Medicare Limited cancelled the acquisition of remaining 76.8% stake in Gujarat Themis Biosyn Limited.	CI
20/05/25	Themis Medicare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025	CI
20/05/25	Themis Medicare Limited Recommends Final Dividend for the Financial Year Ended 31St March 2025	CI
20/05/25	Themis Medicare Limited Enters into Memorandum of Understanding with Gedeon Richter Plc., Hungary	CI
14/02/25	Themis Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024	CI

Chart Themis Medicare Limited

Duration

Period

530199: Dynamic Chart

Company Profile

Themis Medicare Limited is a research-based pharmaceutical company, which is engaged in the manufacturing of pharmaceutical products, especially in formulation and active pharmaceutical ingredients (API) activity. The Company operates through one segment: Pharmaceuticals. The Company manufactures therapeutic pharma products, differential healthcare products, and APIs based in India. The Company specializes in manufacturing a range of products for application areas like pain management, critical care and anti-infectives. Its analgesic and anti-inflammatory products include Aquadol Tpm Gel, Etojet 90 10'S, Etojet 120 10'S, Etojet Mr Tablets 10'S, Etojet XP Gel, Themidol-P Tab 10's, Dhoom, Aquadol inj, Dyloaqua inj, Joydol -P, Joydol -SP, Joydol -TH, and Nimujet Gel. Its Analgesics products include Anemol, Tazowin, Themidol, Themidol. Its Anesthesia products include Bupicaine 0.25%, Ketmin 2 Vial, Ketmin 5, Ropicaine 2, Themicaine 2%, and more.

Employees

1,702

Sector

Pharmaceuticals

More about the company